Alopecia areata treatment
Reading File
Finding Sources
Searching PubMed
"alopecia areata"[MeSH Terms] AND treatment
Reading File
Reading File
Reading File
Reading File
Finding Sources
Reading File
Reading File
Reading File
I now have comprehensive information from multiple authoritative dermatology textbooks and recent literature. Here is a full treatment overview:
Alopecia Areata — Treatment
Pathophysiology (Basis for Treatment)
Alopecia areata (AA) is a T-cell-mediated autoimmune disease. CD8⁺ NKG2D⁺ cytotoxic T cells infiltrate hair follicles, driven by IFN-γ and IL-15 signaling through the JAK-STAT pathway, leading to collapse of hair follicle immune privilege and premature catagen transition. Follicular stem cells are spared, allowing regrowth. This JAK-STAT dependence is the rational basis for JAK inhibitor therapy.
Treatment by Disease Extent
1. Localized / Patchy AA (1st line)
Intralesional corticosteroids — treatment of choice for cosmetically conspicuous patches:
- Triamcinolone acetonide 2.5–5 mg/mL injected intradermally every 3–4 weeks
- ~0.1 mL per site, 1 cm apart; max 10–20 mg per session in adults
- Risk of local atrophy increases with higher concentrations or large volumes
Topical ultrapotent (class I) corticosteroids — safer first-line option; less reliable than injections
Additional topical options:
- Minoxidil (as monotherapy or adjunct)
- Anthralin 1% cream (short-contact, 15–20 min, then wash off)
- Calcineurin inhibitors
- Topical JAK inhibitors (2% tofacitinib, 1.5% ruxolitinib) — less effective than oral forms
- Prostaglandin analogues (bimatoprost, latanoprost) — especially for eyelash/eyebrow involvement
2. Severe / Extensive AA — Systemic Therapy
Indicated when SALT score >20 (Severity of Alopecia Tool).
JAK Inhibitors — Current FDA-Approved Agents ✅
| Drug | Approval | Notes |
|---|---|---|
| Baricitinib (Olumiant) | FDA 2022 — severe AA in adults | JAK1/2 inhibitor; first FDA-approved systemic for AA |
| Ritlecitinib (Litfulo) | FDA — AA with extensive hair loss, age ≥12 | JAK3/TEC inhibitor |
Other JAK inhibitors used off-label: tofacitinib (JAK1/3), ruxolitinib, deuruxolitinib. Maintenance therapy is required to avoid relapse after stopping.
Corticosteroids (Systemic)
- Daily prednisolone 0.4–0.6 mg/kg/day with gradual taper (≥12 weeks) for rapidly progressive disease
- Pulse regimens: dexamethasone 0.1 mg/kg twice weekly, prednisolone 200 mg weekly, or methylprednisolone 500 mg/day × 3 days monthly
-
60% response in widespread patchy AA; ~50% in alopecia totalis; ~25% in universalis
- Predictors of response: disease duration ≤6 months, onset <10 years, multifocal pattern
- Ophiasis pattern typically does not respond
-
Steroid-Sparing / Immunosuppressive Agents
- Cyclosporine 3–5 mg/kg/day
- Methotrexate 15–20 mg/week (0.4 mg/kg/week in children)
- Mycophenolate mofetil, azathioprine, dapsone, sulfasalazine — limited data
- Dupilumab — efficacy mainly in AA co-existing with atopic dermatitis
3. Refractory AA
Contact immunotherapy (topical sensitizers):
- Diphenylcyclopropenone (diphencyprone, DPCP)
- Squaric acid dibutyl ester (SADBE)
- DNCB (dinitrochlorobenzene)
- Preferred in children before systemic therapy; avoid concurrent immunosuppressants (blunts desired inflammatory response)
PUVA (oral/topical methoxsalen + UVA) — option for refractory/widespread disease
308-nm excimer laser — reported regrowth after 11–12 sessions over 9–11 weeks
4. Adjunct Therapy (All Stages)
- Low-dose oral minoxidil can be used as supplemental therapy regardless of primary treatment
Special Populations
| Population | Preferred Approach |
|---|---|
| Children (localized) | Topical steroids, intralesional triamcinolone (with care), contact immunotherapy |
| Children (severe) | Contact immunotherapy before systemic; pulse corticosteroids acceptable; ritlecitinib approved ≥12 yrs |
| Eyebrows/eyelashes | Intralesional steroids, prostaglandin analogues (bimatoprost) |
Prognosis & Counseling Points
- High spontaneous remission rate in patchy AA — must be factored into treatment decisions
- AA totalis and universalis have poorer prognosis and are more treatment-resistant
- Long-standing disease → follicular dropout → may become irreversible
- Screen for associated autoimmune diseases (thyroiditis, SLE, vitiligo) only if clinically indicated
- Biologics (anti-TNF, IL-17 inhibitors) have shown largely disappointing results; AA can even develop during biologic therapy for other conditions
Recent Evidence (2024–2025)
A 2025 network meta-analysis (PMID: 40231941) comparing AA monotherapies confirmed JAK inhibitors as the most effective class. A separate systematic review and network meta-analysis (PMID: 39445776) comparing ritlecitinib vs. baricitinib indirectly found comparable efficacy, supporting both as valid first-choice systemic options.
Sources: Dermatology 2-Volume Set 5e (Elsevier); Andrews' Diseases of the Skin; Fitzpatrick's Dermatology, 9e; Goldman-Cecil Medicine
This is a shared conversation. Sign in to Orris to start your own chat.